Washington, DC, United States of America

Catherine M Bollard

This inventor holds 10 USPTO granted patents and 5 published patent applications and 1 EPO patent. Top assignees: Children's National Medical Center, The George Washington University, Universität Des Saarlandes. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Catherine M Bollard. Retrieved from https://idiyas.com/inventor/catherine-m-bollard

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 5)

% Patents Active = 100.0

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 11(Granted Patents)

Location History:

Bethesda, MD (US) (2018)
Washington, DC (US) (2021 - 2024)

Company Filing History:

10 out of 84

Children's National Medical Center

patents

1 out of 283

The George Washington University

patents

1 out of 18

Universität Des Saarlandes

patents

where one patent can have more than one assignee

Years Active: 2018-2026

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12742153 - FIXED RATIO EX VIVO ACTIVATED MIXED LYMPHOCYTE PRODUCTS FOR USE IN THE TREATMENT OF CANCER (2026-09-22),

2. 12590292 - IMPROVED TARGETED T-CELL THERAPY FOR TREATMENT OF MULTIPLE MYELOMA (2026-03-31),

3. 12478670 - Generating HPV antigen-specific T cells from a naïve T cell population (2025-11-25),

4. 12227590 - Methods and composition for a binding molecule targeting cancer cells expressing SSX2 peptide 41-49 in HLA-A*0201 context (2025-02-18),

5. 12168046 - Mycobacterial antigen compositions and methods of use (2024-12-17),

6. 11999967 - Generating HPV antigen-specific cells from a naive T cell population (2024-06-04),

7. 11931465 - Functionalized Prussian blue nanoparticles, combination Prussian blue nanoparticle-based nano-immunotherapy and applications thereof (2024-03-19),

8. 11649437 - Generating HPV antigen-specific cells from a naive T cell population (2023-05-16),

9. 10934525 - Generating HPV antigen-specific cells from a naive T cell population (2021-03-02),

10. 9885021 - Generation of broadly-specific, virus-immune cells targeting multiple HIV antigens for preventive and therapeutic use (2018-02-06),

Title: The Innovative Journey of Inventor Catherine M. Bollard

Introduction

Catherine M. Bollard, based in Washington, DC, is a prominent inventor in the field of cancer research. With an impressive portfolio of 7 patents, her work focuses on developing novel methods and compositions for treating and detecting cancer, making significant contributions to medical science and patient care.

Latest Patents

Among her latest patents is a groundbreaking invention titled "Methods and composition for a binding molecule targeting cancer cells expressing SSX2 peptide 41-49 in HLA-A*0201 context." This patent encompasses synovial sarcoma X breakpoint 2 binding molecules and methods for their application in the detection and treatment of cancer. Additionally, her patent on "Mycobacterial antigen compositions and methods of use" relates to mycobacterial polynucleotides and polypeptides. This invention includes engineered cells designed to expand T-cells ex vivo, showcasing her dedication to advancing cancer immunotherapy.

Career Highlights

Catherine's impressive career includes significant roles at esteemed institutions such as Children's National Medical Center and Washington University. Her experience in cutting-edge research environments has allowed her to push the boundaries of innovation in cancer treatment.

Collaborations

Throughout her career, Catherine has collaborated with talented professionals, including her notable coworkers Conrad Russell Cruz and Patrick J. Hanley. These collaborations have not only enriched her research but also fostered an environment of innovation and shared knowledge.

Conclusion

Catherine M. Bollard exemplifies the spirit of innovation in the medical field, particularly in cancer research. With her patents and collaborative efforts, she continues to make strides that could transform the landscape of cancer treatment and detection. Her work exemplifies the impact of dedicated inventors on healthcare and the importance of continuous innovation in addressing complex medical challenges.

Profile summary based on public USPTO records.